Wegovy Linked to Normal Liver Fat Levels in Small Analysis of Adults With Obesity

As reported on Medical Daily, small exploratory analysis suggests that semaglutide, the active ingredient in Wegovy, may substantially reduce liver fat in some adults with obesity. However, the findings come…

Continue Reading Wegovy Linked to Normal Liver Fat Levels in Small Analysis of Adults With Obesity

Phase 3 IMAgINATION Trial of Sefaxersen Meets Primary Endpoint in IgA Nephropathy

Investigational once-monthly therapy significantly reduced proteinuria versus placebo at 37 weeks, according to interim findings from the phase 3 study. As reported on PharmaBiz, Roche has reported positive interim findings…

Continue Reading Phase 3 IMAgINATION Trial of Sefaxersen Meets Primary Endpoint in IgA Nephropathy

FDA Grants Priority Review to Imfinzi-Enfortumab Vedotin Regimen for Muscle-Invasive Bladder Cancer

As reported on PharmaBiz, the FDA has accepted AstraZeneca’s supplemental Biologics License Application for durvalumab plus neoadjuvant enfortumab vedotin in patients with muscle-invasive bladder cancer who cannot receive or have…

Continue Reading FDA Grants Priority Review to Imfinzi-Enfortumab Vedotin Regimen for Muscle-Invasive Bladder Cancer